Eisai and Sato Pharmaceutical Restructure Nailin Antifungal Marketing Partnership in Japan
核心洞察
Sato Pharmaceutical (搜索) will take over independent promotion of NAILIN® Capsules 100mg (fosravuconazole) in Japan from April 2026, following the conclusion of its co-promotion agreement with Eisai.
A transitional arrangement has been established where Eisai will continue promotional activities from April 2025 to March 2026, ensuring smooth operational transfer.
The companies have expanded their partnership with a new license agreement for Sato Pharmaceutical (搜索) to develop and commercialize fosravuconazole across Asia and Oceania regions.
Sato Pharmaceutical (搜索) Co., Ltd. and Eisai Co., Ltd. have announced significant changes to their partnership regarding the oral antifungal medication NAILIN® Capsules 100mg (fosravuconazole). The current co-promotion agreement will conclude on March 31, 2025, with Sato Pharmaceutical assuming full promotional responsibilities after a planned transition period.
Under the new agreement, Eisai will continue promotional activities during a one-year transition period from April 1, 2025, to March 31, 2026. Following this period, Sato Pharmaceutical (搜索) will independently manage all promotional operations for the antifungal agent. The arrangement includes a lump sum payment from Sato Pharmaceutical to Eisai.
Product Background and Development
NAILIN® Capsules 100mg, marketed in Japan since July 2018, contains fosravuconazole, an innovative oral antifungal compound developed by Eisai. The drug represents a significant advancement in antifungal therapy, utilizing a prodrug formulation that enhances the solubility and bioavailability of its active component, ravuconazole.
The medication's mechanism of action centers on inhibiting ergosterol biosynthesis, a crucial component of fungal cell membranes. This targeted approach has proven effective in treating various fungal infections, particularly onychomycosis (搜索), for which it received approval in January 2018.
Strategic Partnership Evolution
The relationship between Sato Pharmaceutical (搜索) and Eisai has evolved beyond their initial co-promotion agreement. In July 2024, the companies entered into a broader licensing agreement, granting Sato Pharmaceutical development and commercialization rights across Asia and Oceania. This expanded territory includes ten ASEAN member states, Australia, New Zealand, South Korea, and Taiwan.
The development journey of fosravuconazole in Japan involved collaboration with Seren Pharmaceuticals (搜索) Inc., which initially received exclusive development and commercialization rights from Eisai. This partnership led to successful clinical development and subsequent approval for onychomycosis (搜索) treatment.
This strategic restructuring reflects both companies' commitment to ensuring continued market presence and growth for NAILIN® while optimizing their respective operational strengths in the pharmaceutical market.